Jyong Biotech Ltd.

Jyong Biotech Ltd. (Nasdaq: MENS) is a science-driven biotechnology company based in New Taipei City, Taiwan, dedicated to developing and commercializing plant-derived innovative drugs for urinary system diseases, oncology, and metabolic health. The company's lead botanical drug candidates include MCS-2, targeting urinary health conditions, and MCS-8, which completed a Phase II clinical trial demonstrating statistically significant efficacy in prostate cancer prevention and novel lipid-modulating properties. Jyong Biotech has a multi-regional commercial strategy spanning the U.S., EU, and Asia, with signed MOUs and letters of intent with pharmaceutical distributors in Vietnam and South Korea for MCS-2 market entry. The company secured a global development and commercialization partnership and won the Innovation Gold Award in the Pharmaceutical Category at the 2025 Taipei Biotech Awards. Jyong Biotech listed on Nasdaq in late 2025 and has since advanced toward Phase 3 clinical programs.